Home › GERD › NCT05570448

Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)

Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: A Single Center, Randomized, Sham, Controlled Trial (The AREA Study)

Who can join

Ages 18 to 80 · All sexes

Inclusion Criteria:

* Chronic GERD symptoms (at least 1 typical symptom of GERD, i.e. heartburn or acid reflux/regurgitation at least twice a week) for last 6 months
* Objective evidence of reflux disease (positive ambulatory pH study.)

Exclusion Criteria:

* Patients unable to or unwilling to participate or consent.
* Age \<18 years or \>80 years.
* Allergic or intolerant to PPI medications.
* Large hiatal hernia \> 3 cm and Hill grade IV.
* Barrett's esophagus.
* Esophageal stricture with any prior intervention.
* Major motility disorder.
* Eosinophilic esophagitis.
* Gastroparesis documented by abnormal gastric emptying time.
* Previous fundoplication, myotomy or LINX surgery.
* Cirrhosis with esophageal and/or gastric varices.

About the study

This will be a randomized clinical trial examining the efficacy and safety of ARAT (intervention group) in patients with chronic GERD symptoms (typical symptoms of GERD, i.e. heartburn or acid reflux/regurgitation at least twice a week) for the last 6 months.

Patients must have a positive pH test and a negative manometry (no treatment) procedure.

What is being tested

• ARAT (procedure)
• Sham intervention (control) (procedure)

Sponsor: Midwest Veterans' Biomedical Research Foundation · Participants: 36 · Started: Feb 15, 2022

Contact the study team

• April Higbee, BSN · Phone: 816-861-4700
• Carlissa Campbell, MS · Phone: 816-861-4700

Official record on ClinicalTrials.gov — NCT05570448

Locations in the U.S.

Conditions

• GERD

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.